Menactra Meningococcal Vaccine Description
Menactra contains N meningitidis serogroup 8 A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid 9 protein. N meningitidis A, C, Y, and W-135 strains are cultured on Mueller Hinton agar and 10 grown in Watson Scherp media containing casamino acid.
Menactra Meningococcal Vaccine Indication
Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.
Menactra is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid-, or CRM197-containing vaccine, or to any component of the vaccine.
Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra. GBS has been reported in temporal relationship following administration of Menactra. The decision to give Menactra should be based on careful consideration of the potential benefits and risks.
Menactra Meningococcal Vaccine Dosage
Menactra is administered as an intramuscular injection. The U.S. CDC's ACIP recommends 16-year-old adolescents receive the 2nd dose of MenACWY.
Primary Vaccination: Children 9 months through 23 months of age: Two doses, three months apart. Individuals 2 through 55 years of age: A single dose.
Booster Vaccination: A single booster dose may be given to individuals 15 through 55 years of age at continued risk for meningococcal disease if at least 4 years have elapsed since the prior dose.
Menactra Meningococcal Vaccine Clinical Trials
Sanofi's Menactra Meningococcal Vaccine has been involved in over 40 clinical trials to determine safety and immunogenicity.